CN107752002A - A kind of birch young pilose antler selenium piece of strengthen immunity - Google Patents
A kind of birch young pilose antler selenium piece of strengthen immunity Download PDFInfo
- Publication number
- CN107752002A CN107752002A CN201710973952.5A CN201710973952A CN107752002A CN 107752002 A CN107752002 A CN 107752002A CN 201710973952 A CN201710973952 A CN 201710973952A CN 107752002 A CN107752002 A CN 107752002A
- Authority
- CN
- China
- Prior art keywords
- parts
- pilose antler
- strengthen immunity
- young pilose
- selenium piece
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000018185 Betula X alpestris Nutrition 0.000 title claims abstract description 23
- 235000018212 Betula X uliginosa Nutrition 0.000 title claims abstract description 23
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 23
- 239000011669 selenium Substances 0.000 title claims abstract description 23
- 210000003056 antler Anatomy 0.000 title claims abstract description 22
- 230000036039 immunity Effects 0.000 title claims abstract description 15
- 239000002028 Biomass Substances 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 11
- 229920001353 Dextrin Polymers 0.000 claims abstract description 10
- 239000004375 Dextrin Substances 0.000 claims abstract description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 10
- 235000019425 dextrin Nutrition 0.000 claims abstract description 10
- 229960003685 imatinib mesylate Drugs 0.000 claims abstract description 10
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 10
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 9
- 239000000741 silica gel Substances 0.000 claims abstract description 9
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 9
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims abstract description 8
- 235000013539 calcium stearate Nutrition 0.000 claims abstract description 8
- 239000008116 calcium stearate Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 11
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
- 241000050051 Chelone glabra Species 0.000 claims description 3
- 241000120647 Osbeckia Species 0.000 claims description 3
- 241001251949 Xanthium sibiricum Species 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 2
- 229920003020 cross-linked polyethylene Polymers 0.000 claims description 2
- 239000004703 cross-linked polyethylene Substances 0.000 claims description 2
- 239000003595 mist Substances 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 11
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- 230000002265 prevention Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229960002411 imatinib Drugs 0.000 description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000005453 pelletization Methods 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of birch young pilose antler selenium piece of strengthen immunity, belong to technical field of traditional Chinese medicines, the birch young pilose antler selenium piece of the strengthen immunity is made up of imatinib mesylate, biomass, microcrystalline cellulose, dextrin, calcium stearate, superfine silica gel powder, sodium carboxymethylcellulose etc..Tests prove that immunity can be significantly improved, the generation of pre- anti-cancer.
Description
Technical field
The present invention relates to the birch young pilose antler selenium piece of technical field of health care food, more particularly to a kind of strengthen immunity.
Background technology
In various diseases, cancer is often to occur and be difficult to cure, annual new in spite of advanced medical technology
The incidence of cases of cancer constantly raising, the number for dying from cancer is also continuously increased.Cancer is long-term constantly hair
The process of exhibition, cancer cell and normal cell coexist, and when the immunity function of human body slackens, cancer cell will take advantage of a weak point,
It is on the increase.Development to a certain extent, has reached the process of quantitative change to qualitative change, has also just generated cancerous lesion.World health group
Knit and think that cancer is largely avoidable, the cancer more than 40% can prevent.Tackle the maximally effective hand of cancer
Section is prevention, and some common cancers can be eliminated by prevention.《Cancer in China prevents and controlling planning outline》Pointing out will heavily fortified point
The policy of " putting prevention first " and " regarding rural health as key point " is held, and is done prevention and control of cancer Knowledge Promotion, health education and behavior is strengthened
In advance, whole people's anti-cancer consciousness and the understanding to prevention and control of cancer work are improved.At present it is so-called prevention mainly from degree of fatigue, diet,
Habits and customs etc. are started with, but are produced little effect.Main cause is goed deep into reform and opening-up, and the living standard of people is not
Disconnected to improve, life stress is increasing, and the custom that people are formed for a long time is difficult to caused by changing.The applicant in clinical practice,
A kind of birch young pilose antler selenium piece of strengthen immunity has been developed into, according to clinical verification, the birch young pilose antler selenium piece of the present invention has been taken, people can not influenceed
Normal work, life while, reach the purpose of effective pre- anti-cancer.
The content of the invention
It is an object of the invention to provide a kind of birch young pilose antler selenium piece of strengthen immunity.
The purpose of the present invention is achieved through the following technical solutions, the birch young pilose antler selenium piece of the strengthen immunity by methanesulfonic acid she
Imatinib 6-12 parts, biomass 14-20 parts, microcrystalline cellulose 50-60 parts, -55 parts of DEXTRIN, calcium stearate 6-10 parts, micro mist
Silica gel 10-14 parts, sodium carboxymethylcellulose 17-23 parts, low-substituted hydroxypropyl cellulose 4-7 parts, essence 1-3 parts, the poly- second of crosslinking
Alkene pyrrolidone 2-4 parts are made.
Preferably：9 parts of imatinib mesylate, 17 parts of biomass, 55 parts of microcrystalline cellulose, 48 parts of dextrin, calcium stearate 8
Part, 12 parts of superfine silica gel powder, 20 parts of sodium carboxymethylcellulose, 5 parts of low-substituted hydroxypropyl cellulose, 2 parts of essence, crosslinked polyethylene pyrrole
3 parts of pyrrolidone.
The biomass is by auspicious Siberian cocklebur grass 90-110 parts, Radix Osbeckia Crinitae 45-65 parts, sessile skullcap herb 30-50 parts, CHAGA 20-30
Part crush and to mix, add intense fire heating after the distilled water immersion 30min of its 20 times of weight and boil, use slow fire after boiling instead, keep
Micro-boiling 30min, stirring are filtered while hot, and the dregs of a decoction add the distilled water of 15 times of weight to decoct 30min filtrations, merging filtrate concentration with method again
Powder is dried to, autoclaving is made.
Preparation technology
Imatinib mesylate, biomass, low-substituted hydroxypropyl cellulose, PVPP, crystallite is fine
Dimension element, dextrin put the mixing of high-shearing granulation machine, add sodium carboxymethylcellulose and ethanol in proper amount solution softwood, and taper wet method is whole
Grain machine 5mm screen clothes are dried after wet grain is made, and control 75 DEG C of temperature, 70 DEG C of temperature of charge, and water content≤4% receives grain, and taper is done
Method pelletizing machine 3mm screen cloth whole grains, perfuming essence, superfine silica gel powder, magnesium stearate mix tabletting.
Embodiment
Embodiment one：The birch young pilose antler selenium piece of the present invention is by imatinib mesylate 6g, biomass 14g, microcrystalline cellulose
50g, DEXTRIN g, calcium stearate 6g, superfine silica gel powder 10g, sodium carboxymethylcellulose 17g, low-substituted hydroxypropyl cellulose 4g, perfume (or spice)
Smart 1g, PVPP 2g are made.By imatinib mesylate, biomass, low-substituted hydroxypropyl cellulose, crosslinking
Polyvinylpyrrolidone, microcrystalline cellulose, dextrin put the mixing of high-shearing granulation machine, add sodium carboxymethylcellulose and ethanol in proper amount
Solution softwood, taper wet method pelletizing machine 5mm screen clothes are dried after wet grain is made, and control temperature 45 C, 40 DEG C of temperature of charge, moisture content
Content≤4% receives grain, taper dry method pelletizing machine 3mm screen cloth whole grains, adds peppermint liquid essence, superfine silica gel powder, magnesium stearate to mix
Tabletting.Biological agent is to be crushed to mix by auspicious Siberian cocklebur grass 100g, Radix Osbeckia Crinitae 55g, sessile skullcap herb 40g, CHAGA 25g, adds its 20 times
Intense fire heating is boiled after the distilled water immersion 30min of weight, uses slow fire after boiling instead, keeps micro-boiling 30min, stirs mistake while hot
Filter, the dregs of a decoction add the distilled water of 15 times of weight to decoct 30min filtrations with method again, and merging filtrate is concentrated and dried into powder, autoclaving system
Into.
Embodiment two：The birch young pilose antler selenium piece of the present invention is by imatinib mesylate 9g, biomass 17g, microcrystalline cellulose
55g, dextrin 48g, calcium stearate 8g, superfine silica gel powder 12g, sodium carboxymethylcellulose 20g, low-substituted hydroxypropyl cellulose 5g, perfume (or spice)
Smart 2g, PVPP 3g are made, and preparation method is the same as embodiment one.
Embodiment three：The birch young pilose antler selenium piece of the present invention is by imatinib mesylate 12g, biomass 20g, microcrystalline cellulose
60g, dextrin 55g, calcium stearate 10g, superfine silica gel powder 14g, sodium carboxymethylcellulose 23g, low-substituted hydroxypropyl cellulose 7g, perfume (or spice)
Smart 3g, PVPP 4g are made, and preparation method is the same as embodiment one.
Study on the stability
Accelerated test：By the food piece of the present invention, be positioned over temperature be (34 ± 6) DEG C, the bar that relative humidity is (65 ± 4) %
Placed under part 6 months, sampled respectively at the 1st, 3,6 month, conventionally investigate its stability.As a result show, accelerate
Experiment 6 months, it is each that the present invention respectively obtained by three kinds of embodiments eats the character, content, relevant material, dissolution rate of piece etc.
Inspection target is without significant change, as defined in quality standard in scope.
Long term test：By the medicine of the present invention, be positioned over temperature be (26 ± 8) DEG C, relative humidity be (65 ± 12) %'s
Under the conditions of place 12 months, sampled respectively at the 6th, 12 month, by 2010 years versions《Chinese Pharmacopoeia (two)》Annex it is relevant
Regulation, investigates its stability.As a result show, keep sample experiment 12 months, and the character of sample, content, relevant material, dissolution rate etc. are each
Item inspection target in scope, is illustrating this product steady quality without significant change as defined in quality standard.
Toxicity test
1st, experimental animal cleaning grade healthy SD female rats 100, weight (208 ± 8) g, as chronic toxicity；
Cleaning grade health Kunming female small white mouse 60, weight (22 ± 5) g, as acute toxicological experiment.Feed with normal diet, it is general
Logical drinking-water.Room temperature is controlled in (23 ± 4) DEG C, humidity (55 ± 5) %, natural lighting.
2nd, acute toxicological experiment, 2 groups are randomly divided into from cleaning grade health Kunming female small white mouse 60, test group and
Each 30 of blank control group.Test group is converted to the dosage of small white mouse by normal adult's dose that the oral present invention eats piece daily,
Gavage 2 times daily.Blank control group gives the sodium chloride injection of 1mL/20g weights 0.9% to gavage.
3rd, long term toxicity test cleaning grade healthy SD female rats 100, are randomly divided into 4 groups, control group and test group
It is small, in, it is heavy dose of each 25.Control group gives the sodium chloride injection of 1ml/20g weights 0.9%, test group it is small, in, big agent
Amount group is that adult normal dosage is converted to the 10 of rat dosage, 20,30 times, is gastric infusion.2 times a day, experimental period 3
Individual month.
4th, acute toxicity testing result small white mouse is being administered in 15d without death, to observation post administration mouse outward appearance, hair color, light
Damp normal, social action, reaction are normal, ingest, drain normally.It is artificial after 15d to put to death dissection, observe its heart, liver, spleen
Dirty, lungs, kidney, brain, ovary, uterus are showed no exception.Pathological examination：Yihong of haematine one (HE) is dyed, and test group is dirty
Device surface is smooth, and institutional framework aligned orderly, cell size, form are normal, and endochylema, karyon dyeing are clear, with blank control group
Comparing difference is not statistically significant (P ＞ 0.05).
5th, chronic toxicity result test group it is small, in, outward appearance, the hair color of heavy dose of group and rats in normal control group,
Social action, excitant etc. and not statistically significant (P ＞ 0.05) to the comparing difference such as interest of surrounding environment, food, water.
Increase (P ＜ 0.05) before weight relatively this group experiment after 4 groups of rat experiments, but the equal nothing of weight comparing difference after 4 groups of experiments
Statistical significance (P ＜ 0.05), blood cytology index, blood biochemical analysis index, important organ coefficient ratio after 4 groups of rat experiments
It is not statistically significant (P ＞ 0.05) compared with difference.Important organ row staining pathologic section inspection after 4 groups of rats are put to death, HE dyeing.
Rats in test groups organ tissue structure aligned orderly, cell size, form are normal, and endochylema, karyon dyeing are clear, with control group ratio
Compared with no significant difference (P ＞ 0.05).
Toxicity test shows, toxic reaction is had no after birch young pilose antler selenium piece administration Big and Little Rats of the present invention.
Experimental data
1st, general information selects 6 villages in Linyi City Yinan County, on the basis of villager knows and be voluntary, with the present invention
Birch young pilose antler selenium piece prevented for prevention group, with commercially available methylsulfonic acid imatinib tablet prevented for control group, only with biology
Matter be traditionally made that decoction prevented for observation group, statistics contrast each group patient age, sex, the course of disease, number
There was no significant difference, and (P ＜ 0.05) can carry out comparative study.
The oral birch young pilose antler selenium piece as made from embodiment of the present invention two of 2 prevention method prevention groups, be grown up a 400mg, and one
Day 1 time；The oral methylsulfonic acid imatinib tablet of control group is prevented, and be grown up a 400mg, 1 times a day.Weigh observation group's biology
Matter 400mg is traditionally made decoction point and taken twice sooner or later.Each group is taken withdraws after two months, is adjusted after 2 years
Look into, check between 2 years after the tablet has been ingested, the prevention situation of cancer is as a result as follows.
3rd, prevention result：
| Group | Number of cases | Day dosage | Side effect | Fall ill number | Rate of falling ill (%) |
| Prevention group | 300 | 400mg | Nothing | 0 | 0 |
| Control group | 300 | 400mg | 35 | 4 | 1.33% |
| Observation group | 300 | 400mg | 12 | 6 | 2.00% |
By above prevention result, after identical dose is taken, the prevention group of the birch young pilose antler selenium piece of the present invention is taken,
Be free from side effects in two months generation, and after taking in two years cancer rate is zero, achieve preferable preventive effect.
After control group has 35 people to occur different degrees of nausea,vomiting,diarrhea, muscle cramp, myalgia, fash side effect respectively,
Experiment is exited, and there are 4 people to fall ill in two years after taking.Observation group have 12 people occur respectively different degrees of Nausea and vomiting,
Heating side effect, and there are 6 people to fall ill in two years after taking.Thus illustrate that her horse of the methanesulfonic acid of birch young pilose antler selenium piece of the present invention is replaced
Buddhist nun and biomass have synergistic function, clinic popularization and application.
4th, effect of the birch young pilose antler selenium piece of the present invention to Apoptosis of Breast Cancer is detected
Tested using Flow Cytometry, mitochondrial membrane potential method and Colony forming from many aspects and detect methanesulfonic acid respectively
Imatinib and biomass individually and are used in combination the effect to Apoptosis of Breast Cancer.It was found that imatinib mesylate and biology
Inducing mammary cancer cell-apoptosis is used in combination compared with both are used alone in matter, and apoptosis percentage dramatically increases (P ＜ 0.05), and
The CMXRos fluorescence intensities of mitochondrial membrane potential significantly reduce (P ＜ 0.05), and cell colony Forming ability is substantially inhibited,
I.e. cell monoclonal quantity is decreased obviously (P ＜ 0.05).As a result show, energy is used in combination with biomass in imatinib mesylate
The apoptosis of inducing mammary cancer cell, while reduce the Colony forming ability of breast cancer cancer cell.Therefore the food piece of the present invention is to cancer
Disease also has certain therapeutic action.
Claims (3)
1. the birch young pilose antler selenium piece of a kind of strengthen immunity, it is characterised in that the birch young pilose antler selenium piece of the strengthen immunity by methanesulfonic acid replace by her horse
Buddhist nun 6-12 parts, biomass 14-20 parts, microcrystalline cellulose 50-60 parts, -55 parts of DEXTRIN, calcium stearate 6-10 parts, superfine silica gel powder
10-14 parts, sodium carboxymethylcellulose 17-23 parts, low-substituted hydroxypropyl cellulose 4-7 parts, essence 1-3 parts, crosslinked polyethylene pyrrole
Pyrrolidone 2-4 parts are made.
2. the birch young pilose antler selenium piece of a kind of strengthen immunity as claimed in claim 1, it is characterised in that the birch of the strengthen immunity is fine and soft
Selenium piece is by 9 parts of imatinib mesylate, 17 parts of biomass, 55 parts of microcrystalline cellulose, 48 parts of dextrin, 8 parts of calcium stearate, micro mist silicon
12 parts of glue, 20 parts of sodium carboxymethylcellulose, 5 parts of low-substituted hydroxypropyl cellulose, 2 parts of essence, PVPP 3
Part.
3. the birch young pilose antler selenium piece of a kind of strengthen immunity as claimed in claim 1, it is characterised in that the biomass is by auspicious Siberian cocklebur
Careless 90-110 parts, Radix Osbeckia Crinitae 45-65 parts, sessile skullcap herb 30-50 parts, CHAGA 20-30 parts, which crush, to be mixed, and adds its 20 times of weight
Intense fire heating is boiled after distilled water immersion 30min, uses slow fire after boiling instead, keeps micro-boiling 30min, and stirring is filtered while hot, the dregs of a decoction
Again plus 15 times of weight distilled water with method decoct 30min filtration, merging filtrate be concentrated and dried be made into powder, autoclaving.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710973952.5A CN107752002A (en) | 2017-10-10 | 2017-10-10 | A kind of birch young pilose antler selenium piece of strengthen immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710973952.5A CN107752002A (en) | 2017-10-10 | 2017-10-10 | A kind of birch young pilose antler selenium piece of strengthen immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107752002A true CN107752002A (en) | 2018-03-06 |
Family
ID=61268834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710973952.5A Pending CN107752002A (en) | 2017-10-10 | 2017-10-10 | A kind of birch young pilose antler selenium piece of strengthen immunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107752002A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103222965A (en) * | 2013-01-29 | 2013-07-31 | 青岛大学 | Imatinib mesylate tablet and preparation method thereof |
| CN104337782A (en) * | 2013-08-02 | 2015-02-11 | 山东新时代药业有限公司 | Methanesulfonic acid imatinib tablet |
| CN107115408A (en) * | 2017-05-22 | 2017-09-01 | 沂南县众友中药材种植专业合作社 | It is a kind of to reduce the medicine of methotrexate (MTX) side effect |
| CN107157972A (en) * | 2017-05-06 | 2017-09-15 | 沂南县众友中药材种植专业合作社 | It is a kind of to reduce the medicine of alotec aerosol clinical side effects |
-
2017
- 2017-10-10 CN CN201710973952.5A patent/CN107752002A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103222965A (en) * | 2013-01-29 | 2013-07-31 | 青岛大学 | Imatinib mesylate tablet and preparation method thereof |
| CN104337782A (en) * | 2013-08-02 | 2015-02-11 | 山东新时代药业有限公司 | Methanesulfonic acid imatinib tablet |
| CN107157972A (en) * | 2017-05-06 | 2017-09-15 | 沂南县众友中药材种植专业合作社 | It is a kind of to reduce the medicine of alotec aerosol clinical side effects |
| CN107115408A (en) * | 2017-05-22 | 2017-09-01 | 沂南县众友中药材种植专业合作社 | It is a kind of to reduce the medicine of methotrexate (MTX) side effect |
Non-Patent Citations (1)
| Title |
|---|
| 陈荣辉: "阿司匹林联合雷公藤内酯醇诱导宫颈癌细胞凋亡及其作用机制研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10485832B2 (en) | Chinese herbal oral paste for conditioning qi depression constitution and processing method therefor | |
| CN102885309A (en) | Chloasma removing healthcare food composite and preparation method thereof | |
| CN104366510A (en) | Tea leaf theanine health-care food composition and preparation method thereof | |
| CN101849979B (en) | Chinese medicinal composition granules and preparation method thereof | |
| CN101293063B (en) | Composition for treating climacteric syndrome, preparation and quality control method thereof | |
| CN102000264B (en) | Detection method of composition for treating climacteric syndrome | |
| CN102114170A (en) | Traditional Chinese medicine composition for preventing and treating myocardial ischemia reperfusion injury and preparation method thereof | |
| CN107752002A (en) | A kind of birch young pilose antler selenium piece of strengthen immunity | |
| CN1951447A (en) | Chinese medicinal composition for treating disease of mammary glands and preparation method thereof | |
| CN100423754C (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN101380359A (en) | Jiangu capsules and preparation method thereof | |
| CN102335338B (en) | Chinese medicinal compound preparation for improving parkinson disease brain neurotransmitter metabolism | |
| CN101284076A (en) | New process of Shujinhuoxue pill and quality control method | |
| CN104435298B (en) | A kind of medicine composition for treating depression | |
| KR101470241B1 (en) | Pharmaceutical composition for the prevention or treatment of depression | |
| CN104367673B (en) | A kind of Chinese medicine composition treating Eimeria species | |
| CN103908567B (en) | A kind of compound preparation and its application for treating Painful diabetic neuropathy | |
| CN106389764A (en) | Traditional Chinese medicine preparation, and preparation and application thereof | |
| CN107582667A (en) | A kind of phthisical medicine of clinical treatment | |
| CN104189038A (en) | Traditional Chinese medicine preparation for regulating female physical health and immunity | |
| CN102302624A (en) | Chinese medicinal composition for tonifying liver and kidney | |
| CN112691167B (en) | Traditional Chinese medicine composition for treating depression and preparation and application thereof | |
| CN107929572A (en) | A kind of composition of eliminating phlegm | |
| CN101690794B (en) | Antitumor medicament, preparation method and quality control method | |
| CN101537079A (en) | Pharmaceutical composition or health-care product for improving sleeping and delaying senility and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180306 |